Atossa Therapeutics
NASDAQ: ATOS
$2.44
+0.02
(+0.83%)
as on
Atossa Therapeutics Stock Performance
as on October 10, 2026 at 2:16 pm IST
Day's Low
Day's High
$2.12$2.74
13.11%
Downside
12.30%
Upside
52 Week's Low
52 Week's High
$1.70$18.0030.33%
Downside
637.70%
Upside
Atossa Therapeutics share price movements today
- Previous Close
- $2.42
- Open
- $2.46
- Volume
- 432.7K
- Market Cap
- $24.1M
- Day's Low - High
- $2.12 - $2.74
- 52 Week Low - High
- $1.70 - $18.00
Atossa Therapeutics Historical Returns
- 1 Month Return
- + 4.27 %
- 3 Month Return
- + 2.95 %
- 1 Year Return
- -84.94 %
- 3 Year Return
- -77.09 %
- 5 Year Return
- -94.88 %
Atossa Therapeutics Stock Fundamentals & Key Indicators
Check Atossa Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$24.1M
EPS (TTM)
-4.34
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
-0.56
Industry PE ratio
-3.02
PEG Ratio
0.02
EBITDA
-37.7M
Revenue (TTM)
-
Profit Margin
0.00%
Return On Equity TTM
-102.99%
Atossa Therapeutics vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Atossa Therapeutics with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % | Dividend Yield % |
|---|---|---|---|---|---|---|
| Buy | $24.1M | -94.88% | -0.56 | 0.00% | 0.00% | |
| Neutral | $78.6B | -26.21% | -24.69 | -12.57% | 0.00% | |
| StrongBuy | $127.6B | 185.06% | 29.06 | 86.04% | 0.00% | |
| Buy | $76.4B | 35.73% | 17.66 | 84.86% | 0.50% |
Stock Returns calculator for Atossa Therapeutics Stock including INR - Dollar returns
The Atossa Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.
Investment Value
₹1,00,000
Atossa Therapeutics investment value today
Current value as on today
₹16,395
Returns
Returns from Atossa Therapeutics Stock
Dollar Impact
₹1,333 (+1.33%)
Analyst Recommendation on Atossa Therapeutics Stock
Based on 10 analysts
90.00%
Buy
10.00%
Hold
0.00%
Sell
Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Atossa Therapeutics. Average target price of $19
Atossa Therapeutics Share Price Target
Get share price movements and forecasts by analysts on Atossa Therapeutics.
What analysts predicted
87.16%UPSIDE
Target Price
$19
Current Price
$2.44
Analyzed by
10 Analysts
Target
$19.00
Atossa Therapeutics target price $19, a slight upside of 87.16% compared to current price of $2.44. According to 10 analysts rating.
Indian Investors' Interest in Atossa Therapeutics Stock
Search interest for Atossa Therapeutics Stock has increased by 14% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:14% versus previous 30 day period
Atossa Therapeutics Quarterly Profit & Loss
All numbers in Millions USD
Atossa Therapeutics Annual Profit & Loss
All numbers in Millions USD
Atossa Therapeutics Quarterly Cash Flow
All numbers in Millions USD
Atossa Therapeutics Annual Cash Flow
All numbers in Millions USD
Atossa Therapeutics News & Key Events
Today's Timeline - 09 October
Fri, 05:35 PM
-Atossa announces a stapled contingent value rights agreement, granting CVRs to shareholders tied to future FDA priority review voucher proceeds.
Fri, 06:18 PM
-Atossa's board approves a CVR dividend for shareholders, providing rights to 25% of net proceeds from future FDA priority review voucher.
Fri, 10:01 PM
-Atossa launches Phase 2 trial of (Z)-endoxifen for girls with McCune-Albright Syndrome, targeting early puberty management.
Insights on Atossa Therapeutics
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
NO EFFECTAgainst Peers
In the last 3 years, Moderna, Inc. Common Stock has given 115.5% return, outperforming this stock by 192.6%
- NO EFFECT
Against Peers
In the last 1 year, Moderna, Inc. Common Stock has given 738.6% return, outperforming this stock by 823.5%
NEGATIVE IMPACTPrice Dip
In the last 1 year, ATOS stock has moved down by -84.9%
About Atossa Therapeutics
What is Atos?
Atossa Therapeutics, Inc., popularly called Atos, is a clinical-stage biopharmaceutical company focused on developing innovative treatments in oncology, particularly for breast cancer. It was founded in 2008 and is headquartered in Seattle, Washington. The company was formerly known as Atossa Genetics Inc. before rebranding to Atossa Therapeutics, Inc. in January 2020.
What does Atos do?
Atossa develops targeted therapies for breast cancer and related conditions with a focus on areas of unmet medical need. Its lead candidate, oral (Z)-endoxifen, is an active metabolite of tamoxifen currently in Phase II clinical trials for breast cancer treatment and prevention. The company is also advancing immunotherapy programs, including chimeric antigen receptor (CAR) therapies, to expand its pipeline into other oncology areas.
Atos Products and Programs
| Products/Programs | Description |
| Oral (Z)-Endoxifen | Phase II-stage drug for treatment and prevention of hormone-receptor positive breast cancer |
| Immunotherapy Programs | Development of CAR-based therapies to target cancerous cells |
| Oncology R&D | Focus on novel, targeted treatments for breast cancer and related indications |
| Clinical Trials | Multiple Phase I/II trials evaluating safety and efficacy of pipeline therapies |
| Organisation | Atossa Therapeutics |
| Headquarters | 448 NW Market Street, Seattle, WA, 98107, US |
| Industry | Biotechnology |
| CEO | Steven C. Quay |
Key Management of Atossa Therapeutics
Name | Title |
|---|---|
Ms. Delly Behen P.H.R. | Senior Vice President of Business Operations |
Dr. Richard Graydon M.D., Ph.D. | Interim Chief Medical Officer |
Dr. Steven C. Quay FCAP, M.D., Ph.D. | Chairman, CEO & President |
Mr. Mark J. Daniel CPA | Chief Financial Officer |
Ms. Janet Rose Rea MSPH, RAC | Senior Vice President of Research & Development |
FAQs
What is Atossa Therapeutics share price today?
Atossa Therapeutics share price today is $2.44 as on at the close of the market. Atossa Therapeutics share today touched a day high of $2.74 and a low of $2.12.
What is the 52 week high and 52 week low for Atossa Therapeutics share?
Atossa Therapeutics share touched a 52 week high of $18.00 on and a 52 week low of $1.70 on . Atossa Therapeutics stock price today i.e. is closed at $2.44,which is 86.44% down from its 52 week high and 43.53% up from its 52 week low.
What is Atossa Therapeutics's market capitalisation today?
Atossa Therapeutics market capitalisation is $0.00T as on .
How to invest in Atossa Therapeutics Stock (ATOS) from India?
- Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
- Step 2: Search for Atossa Therapeutics on INDmoney app. Click on Buy button.
What is the minimum amount required to buy Atossa Therapeutics Stock (ATOS) from India?
Indian investors can start investing in Atossa Therapeutics (ATOS) shares with as little as ₹96.730003356934 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹967.30 in Atossa Therapeutics stock (as per the Rupee-Dollar exchange rate as on ).
Based on Atossa Therapeutics share’s latest price of $2.44 as on October 10, 2026 at 8:46 am IST, you will get 4.0984 shares of Atossa Therapeutics. Learn more about
fractional shares .
What are the returns that Atossa Therapeutics has given to Indian investors in the last 5 years?
Atossa Therapeutics stock has given -94.88% share price returns and 27.85% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?